BHBenjamin Haaland

Benjamin Haaland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Haaland has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma

    by Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L. Bowles, et al.

    Patients with advanced melanoma who progress on standard-dose ipilimumab (Ipi) + nivolumab continue to have poor prognosis. Studies support a dose–response activity of Ipi, and one promising combination is Ipi 10 mg/kg (Ipi10) + temozolomide (TMZ). We performed a retrospective cohort analysis of patients with advanced melanoma treated with Ipi10 + TMZ in the immunotherapy refractory/resistant setting (n = 6, all progressed after prior Ipi + nivolumab), using similar patients treated with Ipi3 + TMZ (n = 6) as comparison. Molecular profiling by whole-exome sequencing (WES) and RNA-sequencing (RNA-seq) of tumors harvested through one responder’s treatment was performed. With a median follow up of 119 days, patients treated with Ipi10 + TMZ had a statistically significant longer median progression-free survival of 144.5 days (range 27–219) vs. 44 (26–75) in Ipi 3 mg/kg (Ipi3) + TMZ, p = 0.04, and a trend of longer median overall survival of 154.5 days (27–537) vs. 89.5 (26–548). Two patients in the Ipi10 + TMZ cohort had a partial response, and both responders had BRAF V600E mutant melanoma. RNA-seq showed enrichment of inflammatory signatures, including interferon responses in metastases after Ipi10 + TMZ compared to the primary tumor, and downregulated negative immune regulators. Ipi10 + TMZ demonstrated efficacy, including dramatic responses in patients refractory to prior Ipi + anti-PD1. Molecular data suggest a potential threshold of Ipi dose for activation of sufficient anti-tumor immune response, and higher doses are required for some patients.


  • Protocol for a cluster-randomized trial of a school-based skin cancer preventive intervention for adolescents

    by Yelena P. Wu, Tammy K. Stump, Jennifer L. Hay, David B. Buller, Jakob D. Jensen, Douglas Grossman, Jincheng Shen, Benjamin A. Haaland, Jacey Jones, Kenneth P. Tercyak


  • Open Access

    A Natural Language Processing Algorithm to Improve Completeness of ECOG Performance Status in Real-World Data

    by Aaron B. Cohen, Andrej Rosic, Katherine Harrison, Madeline Richey, Sheila Nemeth, Geetu Ambwani, Rebecca Miksad, Benjamin Haaland, Chengsheng Jiang

    Our goal was to develop and characterize a Natural Language Processing (NLP) algorithm to extract Eastern Cooperative Oncology Group Performance Status (ECOG PS) from unstructured electronic health record (EHR) sources to enhance observational datasets. By scanning unstructured EHR-derived documents from a real-world database, the NLP algorithm assigned ECOG PS scores to patients diagnosed with one of 21 cancer types who lacked structured ECOG PS numerical scores, anchored to the initiation of treatment lines. Manually abstracted ECOG PS scores were used as a source of truth to both develop the algorithm and evaluate accuracy, sensitivity, and positive predictive value (PPV). Algorithm performance was further characterized by investigating the prognostic value of composite ECOG PS scores in patients with advanced non-small cell lung cancer receiving first line treatment. Of N = 480,825 patient-lines, structured ECOG PS scores were available for 290,343 (60.4%). After applying NLP-extraction, the availability increased to 73.2%. The algorithm’s overall accuracy, sensitivity, and PPV were 93% (95% CI: 92–94%), 88% (95% CI: 87–89%), and 88% (95% CI: 87–89%), respectively across all cancer types. In a cohort of N = 51,948 aNSCLC patients receiving 1L therapy, the algorithm improved ECOG PS completeness from 61.5% to 75.6%. Stratification by ECOG PS showed worse real-world overall survival (rwOS) for patients with worse ECOG PS scores. We developed an NLP algorithm to extract ECOG PS scores from unstructured EHR documents with high accuracy, improving data completeness for EHR-derived oncology cohorts.


  • Open Access

    Objectively-Assessed Ultraviolet Radiation Exposure and Sunburn Occurrence

    by Tammy K. Stump, Suzanne Fastner, Yeonjung Jo, Jonathan Chipman, Benjamin Haaland, Elizabeth S. Nagelhout, Ali P. Wankier, Riley Lensink, Angela Zhu, Bridget Parsons, et al.

    Ultraviolet radiation (UVR) exposure is the primary modifiable risk factor for melanoma. Wearable UVR sensors provide a means of quantifying UVR exposure objectively and with a lower burden than self-report measures used in most research. The purpose of this study was to evaluate the relationship between detected UVR exposure and reported sunburn occurrence. In this study, a UVR monitoring device was worn by 97 parent–child dyads during waking hours for 14 days to measure instantaneous and accumulated UVR exposure. The results showed that the participants’ total UVR exposure was associated with reported sunburn after adjusting for Fitzpatrick skin type and geographic location. It was observed that one standard erythemal dose (SED) increase in the participants’ daily total UVR exposure was associated with reported sunburn (an odds ratio (OR) of 1.26 with a 95% CI of 1.13 and 1.41, and p < 0.001 for parents and an OR of 1.28 with a 95% CI of 1.12 and 1.47, and p < 0.001 for children). A one-SED increase in the participants’ UVR exposure from 10 am to 4 pm was also associated with reported sunburn (an OR of 1.31 with a 95% CI of 1.15 and 1.49, and p < 0.001 for parents and an OR of 1.33 with a 95% CI of 1.12 and 1.59, and p = 0.001 for children). We found that elevated UVR exposure recordings measured by the UVR sensor were associated with reported sunburn occurrence. Future directions for wearable UVR sensors may include their use as an intervention tool to support in-the-moment sunburn prevention.


  • Open Access

    Association of Telomere Length with Colorectal Cancer Risk and Prognosis: A Systematic Review and Meta-Analysis

    by Svenja Pauleck, Jennifer A. Sinnott, Yun-Ling Zheng, Shahinaz M. Gadalla, Richard Viskochil, Benjamin Haaland, Richard M. Cawthon, Albrecht Hoffmeister, Sheetal Hardikar

    (1) Background: Colorectal cancer risk and survival have previously been associated with telomere length in peripheral blood leukocytes and tumor tissue. A systematic review and meta-analysis of the literature was conducted. The PubMed, Embase, and Web of Science databases were searched through March 2022. (2) Methods: Relevant studies were identified through database searching following PRISMA guidelines. Risk estimates were extracted from identified studies; meta-analyses were conducted using random effects models. (3) Results: Fourteen studies were identified (eight on risk; six on survival) through systematic review. While no association was observed between circulating leukocyte telomere length and the risk of colorectal cancer [overall OR (95% CI) = 1.01 (0.82–1.24)], a worse survival for those with shorter telomeres in leukocytes and longer telomeres in tumor tissues was observed [Quartile1/Quartile2–4 overall HR (95% CI) = 1.41 (0.26–7.59) and 0.82 (0.69–0.98), respectively]. (4) Conclusions: Although there was no association with colorectal cancer risk, a poorer survival was observed among those with shorter leukocyte telomere length. Future larger studies evaluating a potentially non-linear relationship between telomeres and colorectal cancer are needed.


  • Open Access

    HIAYA CHAT study protocol: a randomized controlled trial of a health insurance education intervention for newly diagnosed adolescent and young adult cancer patients

    by Karely Mann, Austin R. Waters, Elyse R. Park, Giselle K. Perez, Perla L. Vaca Lopez, Heydon K. Kaddas, Echo L. Warner, Nicole Ray, Tomoko Tsukamoto, Karlie Allen, et al.

    Background: For adolescent and young adult (AYA) cancer patients aged 18 to 39 years, health insurance literacy is crucial for an effective use of the health care system. AYAs often face high out-of-pocket costs or have unmet health care needs due to costs. Improving health insurance literacy could help AYAs obtain appropriate and affordable health care. This protocol illustrates a randomized controlled trial testing a virtual health insurance education intervention among AYA patients. Methods: This is a two-arm multisite randomized controlled trial. A total of 80 AYAs diagnosed with cancer in the Mountain West region will be allocated to either usual navigation care or tailored health insurance education intervention with a patient navigator that includes usual care. All participants will complete a baseline and follow-up survey 5 months apart. The primary outcomes are feasibility (number enrolled and number of sessions completed) and acceptability (5-point scale on survey measuring satisfaction of the intervention). The secondary outcomes are preliminary efficacy measured by the Health Insurance Literacy Measure and the COmprehensive Score for financial Toxicity. Discussion: This trial makes a timely contribution to test the feasibility and acceptability of a virtual AYA-centered health insurance education program. Trial registration: ClinicalTrials.gov NCT04448678. Registered on June 26, 2020